Replication of Mini-Sentinel Study Assessing Mirabegron and Cardiovascular Risk in Non-Mini-Sentinel Databases

BACKGROUND: In 2014, the US Food and Drug Administration (FDA) initiated a prospective routine surveillance using the Mini-Sentinel (M-S) program to assess potential signals of acute myocardial infarction (AMI) and stroke with use of mirabegron, indicated for the treatment of overactive bladder (OAB...

Descripción completa

Detalles Bibliográficos
Autores principales: Simeone, Jason C., Nordstrom, Beth L., Appenteng, Kwame, Huse, Samuel, D’Silva, Milbhor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825387/
https://www.ncbi.nlm.nih.gov/pubmed/29134621
http://dx.doi.org/10.1007/s40801-017-0124-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825387/
https://www.ncbi.nlm.nih.gov/pubmed/29134621
http://dx.doi.org/10.1007/s40801-017-0124-7

Ejemplares similares